Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
L647031-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $150.90 | |
L647031-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $250.90 | |
L647031-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $450.90 | |
L647031-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $750.90 | |
L647031-100mg | 100mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,150.90 |
Specifications & Purity | ≥99% |
---|---|
Biochemical and Physiological Mechanisms | Ly93 is a selective and orally active sphingomyelin synthase 2 (SMS2) inhibitor, with an IC 50 of 91 nM. |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Product Description | Ly93 is a selective and orally active sphingomyelin synthase 2 (SMS2) inhibitor, with an IC 50 of 91 nM. In Vivo Ly93 (100 mg/kg, i.g. once daily for 7 days) significantly decreases the plasma SM levels of C57BL/6J mice . Ly93 dose-dependently attenuates the atherosclerotic lesions in the root and the entire aorta as well as macrophage content in lesions, in apolipoprotein E gene knockout mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6J mice . Dosage: 100 mg/kg. Administration: I.G. (gavage) once daily for 7 days. Result: Significantly decreased the plasma SM levels compared with vehicle group. Animal Model: ApoE KO mice (eight-week-old) . Dosage: 12.5 or 40 mg/kg. Administration: I.G. (gavage) once daily. Result: The levels of ALT and AST in the plasma of apoE KO mice did not show statistic changes when compared with the control group. Form:Solid |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Canonical SMILES | CCC1=CC=CC=C1COC2=CC=CC=C2C(=O)NC3=CN=CC=C3 |
---|---|
Isomeric SMILES | CCC1=CC=CC=C1COC2=CC=CC=C2C(=O)NC3=CN=CC=C3 |
PubChem CID | 118911741 |
Molecular Weight | 332.40 |
Enter Lot Number to search for COA:
Solubility | DMSO : 250 mg/mL (752.11 mM; Need ultrasonic) |
---|